KBY Biotech Indexv0.0.34
Search
← Pipeline|Cevivorutinib

Cevivorutinib

Phase 2/3
235-8749
By MedPacto
Source: Trial-derived·Trials: 2
Modality
Bispecific Ab
MOA
HER2
Target
KIF18A
Pathway
T-cell
Hemophilia ACLL
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
Jan 2018
→ Sep 2030
Phase 2Current
NCT05703501
2,847 pts·CLL
2018-01→2030-09·Recruiting
NCT05314277
1,659 pts·CLL
2022-06→2030-09·Recruiting
4,506 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-09-044.4y awayPh3 Readout· CLL
2030-09-114.4y awayPh3 Readout· CLL
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Recruit…
P2/3
Recruit…
Catalysts
Ph3 Readout
2030-09-04 · 4.4y away
CLL
Ph3 Readout
2030-09-11 · 4.4y away
CLL
Recruiting|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT05703501Phase 2/3CLLRecruiting2847EDSS
NCT05314277Phase 2/3CLLRecruiting1659FEV1
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-7809PfizerPhase 1DLL3HER2
NiranesiranJohnson & JohnsonPhase 2KIF18AEGFRi
LLY-8903Eli LillyPreclinicalCD47HER2
SNY-7254SanofiPhase 2CFTRHER2
DatobrutinibSanofiPhase 3AβHER2
TAK-9344TakedaPhase 3CGRPHER2
RiluinavolisibModernaNDA/BLAKIF18APLK4i
NUV-2032NuvalentPreclinicalKIF18ABTKi
VoxaderotideViking TherapeuticsApprovedPD-L1HER2
DNL-9555DenaliPhase 1/2KIF18ACD47i